Abstract
Objectives
To assess the extent of non-indicated vitamin B12- and D-testing among Dutch clinicians and its variation among hospitals.
Design
Cross-sectional study using registration data from 2015 to 2019.
Participants
Patients aged between 18 and 70 years who received a vitamin B12- or D-test.
Primary and secondary outcome measures
The proportion of non-indicated vitamin B12- and D-testing among Dutch clinicians and its variation between hospitals (n=68) over 2015–2019.
Results
Between 2015 and 2019, at least 79.0% of all vitamin B12-tests and 82.0% of vitamin D-tests lacked a clear indication. The number of vitamin B12-tests increased by 2.0% over the examined period, while the number of D-tests increased by 12.2%. The proportion of the unexplained variation in non-indicated vitamin B12- and D-tests that can be ascribed to differences between hospitals remained low. Intraclass correlation coefficients ranged between 0.072 and 0.085 and 0.081 and 0.096 for non-indicated vitamin B12- and D-tests, respectively. The included casemix variables patient age, gender, socioeconomic status and hospital size only accounted for a small part of the unexplained variation in non-indicated testing. Additionally, a significant correlation was observed in non-indicated vitamin B12- and D-testing among the included hospitals.
Conclusion
Hospital clinicians order vitamin B12- and D-tests without a clear indication on a large scale. Only a small proportion of the unexplained variation could be attributed to differences between hospitals.
Keywords: Quality in health care; Hospitals, Public; Clinical Decision-Making; Retrospective Studies
STRENGTHS AND LIMITATIONS OF THIS STUDY.
This study has examined the ordering and appropriateness of vitamin B12- and D-testing among hospital clinicians and its variation using data over several consecutive years.
The use of a detailed nationally representative database allowed us to generate an accurate and reliable overview of the extent of (non-indicated) vitamin B12- and D-testing among exclusively hospital clinicians within the Dutch healthcare system.
Additionally, the use of registration data derived directly from hospital registration systems enabled us to accurately distinguish appropriate from inappropriate vitamin testing using diagnosis codes rather than the proxy of testing interval.
Introduction
Low-value diagnostic testing is a serious problem in most healthcare systems.1 Low-value care is defined as care that offers no net benefit for the patient and which can be associated with harmful outcomes and wasteful spending.2–4 Within diagnostic testing, studies show that both vitamin B12- and D-tests are frequently ordered within medical practice.5–8 However, there are only a few indications that justify the ordering of a vitamin B12- or D-test which are described in international guidelines. Among healthy adults, almost no indications for vitamin B12- and D-testing exist.9 10 International guidelines for hospital clinicians clearly state that vitamin B12- and D-tests should only be ordered in specific scenarios, such as in patients with Coeliac or Crohn’s disease, and not in patients with only vague complaints.9 11–14 Assessments indicate that as much as 77% of vitamin B12-tests and 91% of vitamin D-tests could lack an indication.7 15–23
Studies show that between 8% and 28% of vitamin B12-tests and between 6% and 91% of vitamin D-tests could be non-indicated. Most of these studies have been conducted among general practitioners (GPs).17 19 21 23 Only a few studies have clearly specified that their assessment of the volume of non-indicated vitamin testing concerned hospital clinicians alone. Two studies from Italy reported that on average 17% and 6% of vitamin B12- and D-tests were potentially non-indicated.7 18 However, these assessments used data from a single hospital and therefore do not provide a representative overview. Furthermore, these studies based their assessment of appropriateness on a proxy such as testing interval and not directly by examining the diagnosis for which the test was requested.
In order to address non-indicated vitamin B12- and D-testing, an accurate assessment of the magnitude and variation of non-indicated testing is needed. We therefore aimed to assess both the volume and proportions of patients aged between 18 and 70 years who potentially received non-indicated vitamin B12- and D-tests among Dutch hospital clinicians between 2015 and 2019 using clinical registration data. We also examined the hospital variation in non-indicated vitamin B12- and D-testing in order to identify opportunities for improvement. The proportion of outpatient visits receiving a non-indicated vitamin B12- or D-test among the hospitals included, and the diagnosis codes often associated with vitamin B12- and D-testing over 2019 were also explored. In doing so, we aimed to gain more insight into the volume of non-indicated vitamin testing among hospital clinicians and the diagnoses underlying such testing.
Methods
Design and database
We conducted a cross-sectional study using registration data among Dutch hospital clinicians between 2015 and 2019. Data were obtained from the Dutch National Basic Hospital Care Registration (Landelijke Basisregistratie Ziekenhuiszorg, LBZ).24 The LBZ contains medical, financial and administrative information from all patients undergoing treatment in any Dutch hospital. All vitamin B12- and D-tests ordered by clinicians in Dutch hospitals over the examined time period were extracted; including the associated diagnosis codes, patient age, gender, socioeconomic status (SES) and hospital size. After consulting paediatricians and geriatricians, we limited our analysis to patients aged 18–70 years. Both paediatricians and geriatricians indicated that for patients below 18 and above 70 years, there are many regional screening protocols which also often vary between hospitals. Patients were assigned to one of three age categories; 18–29, 30–49 and 50–70 years. SES scores were derived from a table containing SES scores on the level of four-digit postal codes as published by the Dutch Institute for Social Research in 2017.25 Patients were also assigned to one of six SES categories, based on quintiles calculated with the SES information from all Dutch neighbourhoods. Hospital size was operationalised by assigning a hospital to one of three categories (small/medium/large) based on tertiles calculated using the number of outpatient visits encountered over 2019.
Patient and public involvement
No patients or members of the public were directly involved in the study. Owing to the nature of this study and data privacy constraints, no patients or members of the public were involved in the study design, analysis, interpretation of data or revision of the manuscript.
Analysis of trends in proportions of non-indicated vitamin B12- and D-testing among hospital clinicians
For the assessment of the proportion of justified indication versus non-indicated vitamin B12- and D-testing, we used a service lens, as previously described by Chalmers et al.26 This entails that all vitamin B12- or D-tests ordered were included in our denominator and all vitamin B12- and D-tests ordered with no indication in our numerator. For our distinction of non-indicated vitamin testing, we followed several steps. First, all recommendations regarding vitamin B12- or D-testing were extracted from the relevant guidelines. Initially, we reviewed the Dutch guidelines of hospital clinicians published by the Federation of Medical Specialists for indications for vitamin B12- and D-testing.10 We managed to identify little to no recommendations concerning indications regarding the use of vitamin B12- or D-tests. We therefore chose to supplement these with indications derived from Dutch GP guidelines.13 14 Second, the ICD10 codes corresponding to the diagnoses which warrant the ordering of a vitamin B12- or D-test were collected from these recommendations. Third, the resulting list of ICD10 codes was reviewed by the involved experts to prevent missing relevant codes or diagnoses. We consulted two expert clinicians (an internal medicine physician and a haematologist) in the process of generating the list of indications justifying a vitamin B12- or D-test. Fourth, after completing the list of ICD10 codes, all Clinical Classification Software (CCS) codes associated with these ICD10 codes were extracted from the LBZ database. Subsequently, all Diagnosis-Treatment Combination (DTC) codes associated with the list of relevant CCS codes were extracted. The resulting list was, again, checked for completeness before starting with the assessment of indicated vitamin tests. This process was repeated until all researchers and clinicians agreed on the accuracy of the list of indications justifying vitamin B12- and D-testing. Online supplemental file 1 lists ICD10 and DTC codes used to determine the appropriateness of the identified vitamin B12- or D-tests. It also contains a description of how we identified and linked the identified ICD10 codes to each of the patients included. In an effort to provide potential handles for the design of interventions, we also examined which diagnosis codes were frequently associated with non-indicated tests.
bmjopen-2023-075241supp001.pdf (155.2KB, pdf)
Assessment of hospital variation in non-indicated vitamin B12- and D-testing
Hospital variation in non-indicated vitamin B12- and D- testing was assessed using a multilevel logistic regression analysis, with a random effect for hospital. Separate models per year were made to assess whether the variation in non-indicated vitamin B12- and D-testing was robust over time. Generalised variance inflation factors were calculated to test for collinearity among the included variables before multilevel analysis was conducted (online supplemental file 2). Models were adjusted for the casemix variables: patient age, gender, SES and hospital size. We corrected for patient age, gender and SES, as previous research showed that these affect the amount of care that patients require, receive and have access to.27–31 We included a proxy for hospital size (eg, the total number of outpatient visits in each year) while recent evidence shows that larger healthcare providers tend to provide more low-value care.32 Vitamin tests conducted in patients with a missing SES score or DTC code were excluded from the analysis. Intraclass correlation coefficients (ICCs) were calculated to assess which part of the unexplained variation in non-indicated vitamin B12- and D-testing could be ascribed to differences between the included hospitals, using the method of Snijders and Bosker to assess the error variance.33
bmjopen-2023-075241supp002.pdf (97.4KB, pdf)
Correlation in non-indicated vitamin testing over 2019
Additionally, we also examined whether a correlation existed between the proportions of outpatient visits that received a non-indicated vitamin B12- or D-test over 2019 among the hospitals included. Correlations were assessed using the Pearson correlation coefficient for normally distributed variables and the Spearman correlation coefficient for non-normally distributed variables. Normality was assessed using both density plots and the Shapiro-Wilk test.
Results
Volume vitamin tests among Dutch hospital clinicians
Table 1 provides a general overview of the population characteristics of the population included in our study. Between 2015 and 2019, the number of vitamin B12- and D-tests ordered by clinicians increased by 2.0% (from 275 032 to 280 522) and 12.2% (from 300 013 to 336 736), respectively. A similar trend was also observed in the proportion of patients who received at least one vitamin B12- or D-test, increasing by 2.5% and 11.3% over the examined period. The amount of vitamin B12- and D-tests ordered among women remained almost twice as high compared with men over the entire period examined. Table 2 provides an overview of the outcomes, and online supplemental file 3 contains a more detailed breakdown by gender, age and SES groups on the patient level. The number of patients with at least one vitamin test increases rapidly with age. The included patients, with at least one vitamin B12- or D-test, showed to be more equally distributed over the SES categories. Only in the highest SES category, a slight decrease in the number of patients with a vitamin determination was observed.
Table 1.
Overview of the study population characteristics of the used population over the entire period examined (2015–2019)
| General info regarding the used population between 2015 and 2019 | Number or proportion | Min | Max | Median | IQR |
| Total number of unique patients | 9 214 425 | N.A. | N.A. | N.A. | N.A. |
| Gender (% female) | 64.50% | N.A. | N.A. | N.A. | N.A. |
| Average number of patients among the hospitals (±SD) | 126 722 (±169 110) | 37 | 1 244 526 | 126 722 | 119 601.8 |
| Average number of unique patients among the hospitals (±SD) | 47 561 (±54 317.5) | 32 | 415 673 | 36 561 | 38 590 |
| Average age of the patients included (±SD) | 47.91 (±14.60) | 18 | 70 | N.A. | N.A. |
| Average SES category of the patients included (±SD) | 2.86 (±1.43) | 1 | 6 | N.A. | N.A. |
| Average no. of outpatient visits among the hospitals included | 1 721 337 (±819 148) | 470 117 | 4 659 172 | N.A. | N.A. |
SES, socioeconomic status.
Table 2.
Overview of vitamin B12- and D-tests performed among hospital clinicians over the period examined (2015–2019)
| Year | 2015 | 2016 | 2017 | 2018 | 2019 |
| No. of hospitals included | 63 | 64 | 66 | 69 | 68 |
| Total no. vitamin B12-tests | 275 032 | 265 546 | 279 524 | 279 957 | 280 522 |
| Total no. vitamin B12-tests in hospital with a registered DTC code | 118 126 | 163 244 | 188 063 | 208 012 | 213 308 |
| Vitamin B12-test with a registered DTC without clear indication (%) | 79.0 | 78.0 | 78.2 | 78.3 | 78.1 |
| Total no. of patients with (at least) one vitamin B12-test | 233 541 | 226 999 | 239 033 | 240 063 | 239 351 |
| Total no. of patients with (at least) one vitamin B12-test with a registered DTC code | 103 540 | 141 507 | 162 900 | 178 933 | 183 204 |
| Total no. of patients with (at least) one non-indicated vitamin B12-test (with a registered DTC code) | 83 549 | 111 986 | 128 872 | 141 914 | 145 039 |
| Patients who received at least one vitamin B12-test that was considered non-indicated | 80.7 | 79.1 | 79.1 | 79.3 | 79.2 |
| No. of hospitals included | 62 | 61 | 63 | 65 | 65 |
| Total no. vitamin D-tests | 300 013 | 300 427 | 322 703 | 323 074 | 336 736 |
| Total no. vitamin D-tests in hospital with a registered DTC code | 121 892 | 179 271 | 208 361 | 230 620 | 242 040 |
| Vitamin D-test with a registered DTC without clear indication (%) | 82.5 | 82.9 | 82.7 | 82.5 | 82.0 |
| Total no. of patients with (at least) one vitamin D-test | 244 834 | 247 186 | 264 811 | 265 362 | 272 380 |
| Total no. of patients with (at least) one vitamin D-test with a registered DTC code | 101 932 | 148 660 | 172 342 | 189 423 | 196 452 |
| Total no. of patients with (at least) one non-indicated vitamin D-test (with a registered DTC code) | 84 414 | 124 162 | 143 408 | 157 431 | 162 345 |
| Patients who received at least one vitamin B12-test that was considered non-indicated (%) | 82.8 | 83.5 | 83.2 | 83.1 | 82.6 |
DTC, Diagnosis Treatment Combination.
bmjopen-2023-075241supp003.pdf (130.6KB, pdf)
Non-indicated testing
Between 2015 and 2019, around 78% of the vitamin B12-tests conducted among patients aged between 18 and 70 years, with a registered DTC code, lacked an indication. In the case of vitamin D-testing, around 82% of determinations had no clear indication. Although the number of vitamin tests is higher among women, no large differences in proportions of non-indicated testing were observed between genders. In the case of both age and SES, the proportion of patients with a non-indicated vitamin B12- or D-test remains relatively constant across all groups over the study period (online supplemental file 3). With the proportion of non-indicated testing remaining around 80.0% for vitamin B12 and 83.5% for vitamin D across the different age and SES. Our analysis of diagnosis codes that are most often associated with non-indicated vitamin B12- and D-testing revealed that tests are ordered for various reasons. Similar diagnostic codes were associated with both non-indicated vitamin B12- and D-tests, including general malaise, fatigue without diagnosis and ulcerative colitis. Online supplemental file 4 contains an overview of the top 20 diagnosis codes for both vitamin B12- and D-tests.
bmjopen-2023-075241supp004.pdf (95.6KB, pdf)
Hospital variation in non-indicated vitamin B12- and D-tests among Dutch hospital clinicians
The ICCs of the models uncorrected for casemix remained around 9% (ranging from 8.3% to 9.5%) and 9.5% (ranging from 8.5% to 10.1%) for the vitamin B12- and D-models over time. The ICCs of the casemix-corrected vitamin B12- and D-models remained stable around 8.0% (ranging between 7.2% and 8.5%) and 9% (ranging between 8.1% and 9.6%), respectively, throughout the examined period. Online supplemental file 5 contains the ICCs of all models. Casemix correction minimally impacted the calculated ICCs in the case of both the vitamin B12- and D-models. The proportion of outpatient visits receiving a non-indicated vitamin B12- or D-test over 2019 varied widely among the hospitals included, ranging from 0% to 27.6% for vitamin B12 and 0.02% to 34.8% for vitamin D (see figure 1 and online supplemental file 6).
Figure 1.
Proportion of all outpatient visits at each of the included hospitals that received a low-value vitamin (A) B12- or (B) D-test over 2019 (n=68).
bmjopen-2023-075241supp005.pdf (81.3KB, pdf)
bmjopen-2023-075241supp006.pdf (110.9KB, pdf)
Correlation in proportions of non-indicated vitamin B12- and D-testing
Normality testing (and inspection of density plots) revealed that both the proportions of vitamin B12- and D-testing observed among the hospitals are non-normally distributed. The subsequent correlation analysis revealed the presence of a significant positive correlation (r=0.86, p<0.001) between the proportions of non-indicated vitamin B12- and D-testing among the included hospitals. Online supplemental file 7 contains the density plots, normality test results and correlation analysis outcomes for both non-indicated vitamin B12- and D-tests.
bmjopen-2023-075241supp007.pdf (515KB, pdf)
Discussion
Between 2015 and 2019, around 78.0% and 82.0% of vitamin B12- and D-tests ordered by Dutch hospital clinicians in patients aged 18–70 lacked a clear indication. The total number of vitamin B12-tests ordered increased by 2.0%, while the total number of vitamin D-tests increased by 12.2%. Although the total number of vitamin determinations increased, the proportion of patients with at least one vitamin test remained relatively constant (around 80% for vitamin B12 and 83% for vitamin D). Women received approximately twice as many vitamin B12- and D-tests, as well as non-indicated tests, over the examined period compared with men. Our analysis of hospital variation in non-indicated vitamin B12- and D-testing revealed a moderate hospital variation. Furthermore, only a relatively small part of the unexplained variation in non-indicated vitamin B12- and D- testing could be ascribed to differences between the hospitals included, suggesting that the problem of non-indicated vitamin testing is present among all hospitals. Correlation analysis over 2019 revealed a fairly strong positive (r=0.86) correlation between the rates of non-indicated vitamin B12- and D-testing among the hospitals included.
Comparison to existing literature
The proportion of non-indicated vitamin B12- and D-testing among clinicians found in our study (78.0% and 82.0%, respectively) is substantially larger than the proportions reported by other studies. For example, two studies from Italy conducted among hospital clinicians report that on average 17.0% and 6.0% of vitamin B12- and D-tests could potentially be non-indicated,7 18 which is substantially lower than the proportions observed in our study. Our findings are more in line with assessments that are not limited to hospital clinicians. Hence, studies conducted among GPs indicate that between 8.0% and 28.0% of vitamin B12-tests7 15 16 18 and between 7.0% and 91.0% of vitamin D-tests could be considered non-indicated.7 15 19 21 23 Among these studies, only Naugler et al and Gonzalez-Chica reported proportions of non-indicated vitamin D testing which is similar to ours. Naugler et al, found that following an intervention the prevalence of non-indicated vitamin D-testing decreased by 91.4%.19 While Gonzalez-Chica reported 76.5% of vitamin D-tests to be non-indicated after the introduction of new Medicare criteria for rebates. Besides population differences (eg, GPs vs hospital clinicians), varying definitions of non-indicated testing and methods used could also account for the large differences in assessment outcomes. For example, both our study and that of Naugler et al used diagnosis codes to distinguish the appropriateness of vitamin testing.19 Most assessments of the appropriateness of vitamin testing performed to date used testing intervals or laboratory results to discern non-indicated testing, as did Gonzalez-Chica.23 This methodological difference might explain the large differences in assessment outcomes. Furthermore, the studies that did not limit their assessment to vitamin testing among GPs were often conducted within a single hospital.7 18 Moreover, most studies that assessed vitamin B12- or D-testing do not specify which type of physicians (GP/hospital clinicians) or vitamin B12- and D-tests were included, making comparison to our study challenging.
The absence of clear recommendations regarding the ‘appropriate’ use of vitamin testing in clinician guidelines does not aid clinicians to appropriately order vitamin testing. The current guidelines for hospital clinicians offer little direction on the appropriate use of vitamin B12- or D-tests, leaving clinicians with little guidance when deciding whether to order such tests. These difficulties are magnified by the large knowledge gaps regarding the exact roles of vitamin B12 and D within the human body and its metabolism.34–37 The combination of these factors may provide an explanation for the high proportion of non-indicated testing. Hence, due to the lack of a clear understanding of the roles of vitamin B12 and D within the body and the fear of missing a diagnosis, clinicians may engage in defensive behaviour resulting in the ordering of vitamin tests.
Strengths and limitations
A strength of this study is its novelty in examining the ordering and appropriateness of vitamin B12- and D-testing among hospital clinicians and its variation over several consecutive years. A second strength is that we used a detailed nationally representative database. This allowed us to generate an accurate and reliable overview of the extent of vitamin B12- and D-testing among solely hospital clinicians. Furthermore, it also enabled us to accurately distinguish appropriate from inappropriate vitamin testing using diagnosis codes rather than the proxy of testing interval.
However, our study is also prone to limitations. First, we based our distinction of appropriateness mainly on expert opinion and indications derived from the Dutch GP guidelines, as no universal guideline regarding vitamin testing among hospital clinicians exists. We therefore might have misclassified some of the tests from clinicians as being non-indicated. However, we tried to minimise the risk of misclassification by closely collaborating with the involved experts with respect to the creation of the list of indications. Additionally, some differences exist between international and Dutch guidelines regarding indications for vitamin B12- and D-testing. For example, guidelines from the USA indicate that vitamin B12-testing is considered indicated in patients with cognitive impairments or dementia.38 However, these are not considered as an indication according to the nationwide guidelines published by the Dutch federation of medical specialists.10 Potentially, such recommendations could exist in local protocols of Dutch hospitals, which unfortunately are not publicly available. This makes it difficult to compare international assessment outcomes to our study, while subtle differences between guidelines might cause large differences in the used criteria of appropriateness (and subsequently the reported outcomes).
Second, the use of DTC codes enabled us to accurately distinguish the appropriateness of vitamin tests but also has a drawback. DTC diagnosis codes are generally less specific compared with the ICD10 codes described in the used guidelines. We therefore might have misclassified some vitamin tests as being appropriate. Furthermore, although DTC diagnosis codes provide a lot of insight into the diagnosis associated with practices, their registration is prone to misregistration.39 Clinicians have a vast amount of (often similar) DTC codes to choose from when registering a diagnosis code, thereby adding another layer of complexity to the correct registration of diagnoses. Furthermore, DTC codes are updated as the patient passes through the healthcare system. The registered DTC code therefore does not necessarily represent the initial reason (or diagnosis) for which the vitamin determination was ordered but rather reflects the final diagnosis.
Third, some Dutch hospitals outsource their tests to external commercial laboratories, which are not registered in the LBZ. Our estimate of vitamin testing by clinicians therefore is not complete. However, according to the registration of the National Statistical Office, Statistics Netherlands, 82 hospitals were active in 2019. Since we were able to include data from the majority of the hospitals in the Netherlands in our study (68/82, eg, 83.0% of all hospitals), we do not expect to have missed much in our analysis.40
Implications for research and practice
Our assessment reveals that a large proportion of vitamin B12- and D- tests are ordered without a clear indication justifying their use. The total volumes of vitamin B12- and D-tests have increased over the years and show no inclination of declining. Based on publicly available fares, we estimate that roughly €3.8 million has been spent on non-indicated vitamin B12- and D-tests in 2019 by Dutch hospital clinicians alone.41 This estimate of the potential savings, however, is very rough, while it only accounts for the cost price of a vitamin B12- or D-determination. The observed incidence rates of non-indicated vitamin B12- and D-testing, however, suggest that there is ample opportunity to reduce vitamin testing among Dutch clinicians. Especially since non-indicated vitamin B12- and D-tests are often ordered for similar diagnoses, and a positive correlation exists between the proportions of non-indicated testing within the same hospitals. We know that there are effective interventions to reduce inappropriate vitamin testing among GPs. A study among Dutch GPs showed that providing both education and feedback successfully reduced the amount of vitamin tests ordered by 20%–25%.42 Similar interventions might therefore also be effective among hospital clinicians to reduce (non-indicated) vitamin testing. Alternatively, more emphasis could be placed on the institution of fortification and supplementation guidelines to achieve adequate vitamin B12 and D intake among the Dutch population. Especially since, the implementation of such guidelines have shown to positively affect vitamin status among the population rendering vitamin testing obsolete in most cases.43–45 Future research could focus on further examination of patient and physicians’ characteristics associated with non-indicated vitamin B12- and D-testing. Unfortunately, information regarding the requesting physician (age, sex, etc) of non-indicated tests was not available to us in our study. Insight into physician characteristics associated with non-indicated testing could aid in the design of interventions aiming to address the problem of non-indicated vitamin testing.
Conclusion
Our research shows that the number of vitamin B12-tests slightly increased over the examined time period, while the number of vitamin D tests substantially increased among hospital clinicians. Throughout the examined period, the proportion of B12- and D-tests without clear indication remained high and is substantially higher compared with similar (international) assessments. The observed difference in assessment outcome can potentially be explained by differences in methods and definitions used to identify and define non-indicated vitamin B12- and D-tests (eg, the use of associated diagnosis codes instead of test results or proxies such as testing interval). We also observed the presence of moderate hospital variation, but this variation could not be explained by the included patient and hospital characteristics age, sex, SES and hospital size. Hospitals hardly differ in the task they have to undertake: bring down the number of non-indicated B12- and D-tests.
Supplementary Material
Acknowledgments
The authors would like to thank Professor Dr P. Lips, Professor Emeritus, APH—Aging & Later Life, Professor Emeritus of Internal Medicine, Visiting Fellow Internal Medicine from the Amsterdam UMC, Dr L. de Boer and Dr A. Dittrich for their critical review and contributions to the paper.
Footnotes
Twitter: @tijnkool
Contributors: Conceptualisation: JLJMM, RBK, SAvD and GPW. Data curation: MZ. Formal analysis: JLJMM and FA. Funding acquisition: RBK and SAvD. Guarantor of overall content: JLJMM. Investigation: JLJMM, RBK, SAvD and HM. Methodology: JLJMM and FA. Project administration: JLJMM. Resources: MZ. Software: JLJMM. Supervision: RBK, SAvD and GPW. Validation: JLJMM, RBK and SAvD. Visualisation: JLJMM. Writing—original draft preparation: JLJMM, RBK and SAvD. Writing—review and editing: JLJMM, RBK, SAvD, MZ, HM, FA and GPW.
Funding: This work was supported by ZonMw, the Dutch organization for Health Research and Development (grant number 839205002). The funder had no role in the design and conduct of the study.
Competing interests: None declared.
Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review: Not commissioned; externally peer reviewed.
Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Data availability statement
Data are available upon reasonable request. The source data are not freely available. However, the data used to conduct our analysis are available upon reasonable request after consultation with the data supplier.
Ethics statements
Patient consent for publication
Not applicable.
Ethics approval
The protocol for this research was approved by the Research Ethics Committee of the Radboud University Medical Centre (dossier number 2020-6767). Informed consent of individual patients was not required as anonymised information was obtained from medical records.
References
- 1. Müskens JLJM, Kool RB, van Dulmen SA, et al. Overuse of diagnostic testing in Healthcare: a systematic review. BMJ Qual Saf 2022;31:54–63. 10.1136/bmjqs-2020-012576 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Brownlee S, Chalkidou K, Doust J, et al. Evidence for overuse of medical services around the world. Lancet 2017;390:156–68. 10.1016/S0140-6736(16)32585-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Colla CH, Mainor AJ, Hargreaves C, et al. Interventions aimed at reducing use of low-value health services: A systematic review. Med Care Res Rev 2017;74:507–50. 10.1177/1077558716656970 [DOI] [PubMed] [Google Scholar]
- 4. Scott IA, Duckett SJ. In search of professional consensus in defining and reducing low-value care. Med J Aust 2015;203:179–81. 10.5694/mja14.01664 [DOI] [PubMed] [Google Scholar]
- 5. Essig S, Merlo C, Reich O, et al. Potentially inappropriate testing for vitamin D deficiency: a cross-sectional study in Switzerland. BMC Health Serv Res 2020;20:1097. 10.1186/s12913-020-05956-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Crowe FL, Jolly K, MacArthur C, et al. Trends in the incidence of testing for vitamin D deficiency in primary care in the UK. BMJ Open 2019;9:e028355. 10.1136/bmjopen-2018-028355 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Lanzoni M, Fornili M, Felicetta I, et al. Three-year analysis of repeated laboratory tests for the markers total cholesterol, Ferritin, vitamin D, vitamin B(12), and folate, in a large research and teaching hospital in Italy. J Eval Clin Pract 2017;23:654–61. 10.1111/jep.12696 [DOI] [PubMed] [Google Scholar]
- 8. O’Sullivan JW, Stevens S, Hobbs FDR, et al. Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. BMJ 2018;363:k4666. 10.1136/bmj.k4666 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. American Society for Clinical Pathology . Thirty five things physicians and patients should question. 2021. Available: https://www.choosingwisely.org/clinician-lists/ascp-do-not-order-red-blood-cell-folate-levels/
- 10. Richtlijnen database . Federatie Medisch Specialisten. 2022. Available: https://richtlijnendatabase.nl/
- 11. Dutch College of Clinical Chemistry and Laboratory Medicine & College of medical immunologists . Verstandige Keuzes Bij Het Aanvragen En Interpreteren van Laboratoriumdiagnostiek 2015. [Google Scholar]
- 12. Canadian Association of Pathologists . Choosingwisely Canada Pathology Recommendations. 2021. [Google Scholar]
- 13. Nederlands Huisartsen Genootschap . Laboratoriumdiagnostiek Vitamine B12-Deficiëntie (LESA): NHG. 2018. Available: https://www.nhg.org/themas/publicaties/laboratoriumdiagnostiek-vitamine-b12-volledige-tekst
- 14. Nederlands Huisartsen Genootschap . Vitamine D-Deficiëntie (LESA Laboratoriumdiagnostiek): NHG. 2018. Available: https://www.nhg.org/themas/publicaties/vitamine-d-deficientie-samenvatting?tmp-no-mobile=1]
- 15. Chami N, Simons JE, Sweetman A, et al. Rates of inappropriate laboratory test utilization in Ontario. Clin Biochem 2017;50:822–7. 10.1016/j.clinbiochem.2017.05.004 [DOI] [PubMed] [Google Scholar]
- 16. Morgen EK, Naugler C. Inappropriate repeats of six common tests in a Canadian city: a population cohort study within a laboratory Informatics framework. Am J Clin Pathol 2015;144:704–12. 10.1309/AJCPYXDAUS2F8XJY [DOI] [PubMed] [Google Scholar]
- 17. Gill P, Guo M, Lau CK, et al. Vitamin B12 test volume data before and after the implementation of an educational province-wide intervention to reduce redundant testing in Alberta. Data Brief 2019;27:104785. 10.1016/j.dib.2019.104785 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Tamburrano A, Vallone D, Carrozza C, et al. Evaluation and cost estimation of laboratory test Overuse in 43 commonly ordered parameters through a computerized clinical decision support system (CCDSS) in a large University hospital. PLoS One 2020;15:e0237159. 10.1371/journal.pone.0237159 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Naugler C, Hemmelgarn B, Quan H, et al. Implementation of an intervention to reduce population-based screening for vitamin D deficiency: a cross-sectional study. CMAJ Open 2017;5:E36–9. 10.9778/cmajo.20160073 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Colla CH, Morden NE, Sequist TD, et al. Choosing wisely: prevalence and correlates of low-value health care services in the United States. J Gen Intern Med 2015;30:221–8. 10.1007/s11606-014-3070-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Mafi JN, Reid RO, Baseman LH, et al. Trends in low-value health service use and spending in the US Medicare fee-for-service program, 2014-2018. JAMA Netw Open 2021;4:e2037328. 10.1001/jamanetworkopen.2020.37328 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Zorginstituut Nederland . Screeningsrapport Endocriene Ziekten; voedings- en stofwisselingstoornissen. Zorginstituut Nederland, 2018. [Google Scholar]
- 23. Gonzalez-Chica D, Stocks N. Changes to the frequency and appropriateness of vitamin D testing after the introduction of new Medicare criteria for rebates in Australian general practice: evidence from 1.5 million patients in the NPS Medicineinsight database. BMJ Open 2019;9:e024797. 10.1136/bmjopen-2018-024797 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Dutch Hospital Data . Landelijke Basisregistratie Zorg (LBZ). Data DH, [Google Scholar]
- 25. The Netherlands Institute for Social Research . The Netherlands Institute for Social Research (SCP). Netherlands: Statusscores, 2017. [Google Scholar]
- 26. Chalmers K, Pearson SA, Elshaug AG. Quantifying low-value care: a patient-centric versus service-centric lens. BMJ Qual Saf 2017;26:855–8. 10.1136/bmjqs-2017-006678 [DOI] [PubMed] [Google Scholar]
- 27. McMaughan DJ, Oloruntoba O, Smith ML. Socioeconomic status and access to Healthcare: interrelated drivers for healthy aging. Front Public Health 2020;8:231. 10.3389/fpubh.2020.00231 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Arpey NC, Gaglioti AH, Rosenbaum ME. How socioeconomic status affects patient perceptions of health care: A qualitative study. J Prim Care Community Health 2017;8:169–75. 10.1177/2150131917697439 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Asch SM, Kerr EA, Keesey J, et al. Who is at greatest risk for receiving poor-quality health care N Engl J Med 2006;354:1147–56. 10.1056/NEJMsa044464 [DOI] [PubMed] [Google Scholar]
- 30. David JL, Kaplan HB. Gender, social roles and health care utilization. Applied Behavioral Science Review 1995;3:39–64. 10.1016/S1068-8595(95)80012-3 [DOI] [Google Scholar]
- 31. Bertakis KD, Azari R, Helms LJ, et al. Gender differences in the utilization of health care services. J Fam Pract 2000;49:147–52. [PubMed] [Google Scholar]
- 32. Segal JB, Sen AP, Glanzberg-Krainin E, et al. Factors associated with Overuse of health care within US health systems: A cross-sectional analysis of Medicare beneficiaries from 2016 to 2018. JAMA Health Forum 2022;3:e214543. 10.1001/jamahealthforum.2021.4543 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Snijders TAB, Bosker RJ. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel. Modeling: SAGE Publications, 2011. [Google Scholar]
- 34. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81. 10.1056/NEJMra070553 [DOI] [PubMed] [Google Scholar]
- 35. Green R, Miller JW. Chapter fifteen - vitamin B12 deficiency. In: Litwack G, ed. Vitamins and Hormones. 119: Academic Press, 2022: 405–39. [DOI] [PubMed] [Google Scholar]
- 36. Rebelos E, Tentolouris N, Jude E. The role of vitamin D in health and disease: A narrative review on the mechanisms linking vitamin D with disease and the effects of supplementation. Drugs 2023;83:665–85. 10.1007/s40265-023-01875-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Halczuk K, Kaźmierczak-Barańska J, Karwowski BT, et al. Vitamin B12 — Multifaceted in vivo functions and in vitro applications. Nutrients 2023;15:2734. 10.3390/nu15122734 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Neurology 2001;56:1143–53. 10.1212/WNL.56.9.1143 [DOI] [PubMed] [Google Scholar]
- 39. Marcotte LM, Schuttner L, Liao JM. Measuring low-value care: learning from the US experience measuring quality. BMJ Qual Saf 2020;29:154–6. 10.1136/bmjqs-2019-010191 [DOI] [PubMed] [Google Scholar]
- 40. Statistics Netherlands (CBS) [Zorginstellingen; kerngetallen]. 2019.
- 41. Diagnostiek voor u . Fares 2022-2023. 2023. Available: https://diagnostiekvooru.nl/tarieven
- 42. Vugt S van, de Schepper E, van Delft S, et al. Effectiveness of professional and patient-oriented strategies in reducing vitamin D and B12 test ordering in primary care: a cluster randomised intervention study. BJGP Open 2021;5:BJGPO.2021.0113. 10.3399/BJGPO.2021.0113 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Itkonen ST, Andersen R, Björk AK, et al. Vitamin D status and current policies to achieve adequate vitamin D intake in the Nordic countries. Scand J Public Health 2021;49:616–27. 10.1177/1403494819896878 [DOI] [PubMed] [Google Scholar]
- 44. Jääskeläinen T, Itkonen ST, Lundqvist A, et al. The positive impact of general vitamin D food Fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-Y follow-up based on standardized 25-Hydroxyvitamin D data. Am J Clin Nutr 2017;105:1512–20. 10.3945/ajcn.116.151415 [DOI] [PubMed] [Google Scholar]
- 45. Das JK, Salam RA, Mahmood SB, et al. Food Fortification with multiple Micronutrients: impact on health outcomes in general population. Cochrane Database Syst Rev 2019;12:CD011400. 10.1002/14651858.CD011400.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
bmjopen-2023-075241supp001.pdf (155.2KB, pdf)
bmjopen-2023-075241supp002.pdf (97.4KB, pdf)
bmjopen-2023-075241supp003.pdf (130.6KB, pdf)
bmjopen-2023-075241supp004.pdf (95.6KB, pdf)
bmjopen-2023-075241supp005.pdf (81.3KB, pdf)
bmjopen-2023-075241supp006.pdf (110.9KB, pdf)
bmjopen-2023-075241supp007.pdf (515KB, pdf)
Data Availability Statement
Data are available upon reasonable request. The source data are not freely available. However, the data used to conduct our analysis are available upon reasonable request after consultation with the data supplier.

